Does the media prefer ASND or MRNA?

In the previous week, Moderna had 47 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 81 mentions for Moderna and 34 mentions for Ascendis Pharma A/S. Moderna's average media sentiment score of 0.61 beat Ascendis Pharma A/S's score of 0.49 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 5 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 39 Very Positive mention(s) 15 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 8 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ASND or NTRA?

Natera has higher revenue and earnings than Ascendis Pharma A/S. Natera is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 19.93 -$258M $12.89 20.19 Natera $2.31B 20.05 -$208.16M -$1.36 N/A

Does the media prefer ASND or NTRA?

In the previous week, Natera had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 35 mentions for Natera and 34 mentions for Ascendis Pharma A/S. Natera's average media sentiment score of 1.25 beat Ascendis Pharma A/S's score of 0.49 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 5 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Natera 29 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor RVMD or ASND?

In the previous week, Revolution Medicines had 36 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 70 mentions for Revolution Medicines and 34 mentions for Ascendis Pharma A/S. Revolution Medicines' average media sentiment score of 0.84 beat Ascendis Pharma A/S's score of 0.49 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 33 Very Positive mention(s) 10 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 5 Very Negative mention(s) Positive Ascendis Pharma A/S 5 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ASND or BIIB?

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 19.93 -$258M $12.89 20.19 Biogen $9.89B 3.23 $1.29B $5.65 38.24

Does the media refer more to ASND or BIIB?

In the previous week, Biogen had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 36 mentions for Biogen and 34 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 1.30 beat Ascendis Pharma A/S's score of 0.49 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 5 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 29 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASND or ALNY?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 34 mentions for Ascendis Pharma A/S and 28 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.05 beat Ascendis Pharma A/S's score of 0.49 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 5 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 20 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ascendis Pharma A/S (ASND) Competitors

$260.25 -2.79 (-1.06%)

As of 09/1/2026 04:00 PM Eastern

Compare

ASND vs. MRNA, NTRA, RVMD, BIIB, and ALNY

Should you buy Ascendis Pharma A/S stock or one of its competitors? Ascendis Pharma A/S's main competitors and comparable companies include Moderna (MRNA), Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascendis Pharma A/S compare to Moderna?

Ascendis Pharma A/S (NASDAQ:ASND) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Ascendis Pharma A/S has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.93	-$258M	$12.89	20.19
Moderna	$1.94B	31.68	-$2.82B	-$7.99	N/A

Ascendis Pharma A/S has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to Moderna's net margin of -141.43%. Ascendis Pharma A/S's return on equity of 32.54% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Moderna	-141.43%	-28.30%	-19.39%

Ascendis Pharma A/S presently has a consensus target price of $310.05, indicating a potential upside of 19.14%. Moderna has a consensus target price of $80.53, indicating a potential downside of 47.80%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Moderna	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Moderna had 47 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 81 mentions for Moderna and 34 mentions for Ascendis Pharma A/S. Moderna's average media sentiment score of 0.61 beat Ascendis Pharma A/S's score of 0.49 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	39 Very Positive mention(s)	15 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	8 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Natera?

Ascendis Pharma A/S (NASDAQ:ASND) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Ascendis Pharma A/S has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

In the previous week, Natera had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 35 mentions for Natera and 34 mentions for Ascendis Pharma A/S. Natera's average media sentiment score of 1.25 beat Ascendis Pharma A/S's score of 0.49 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natera	29 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

99.9% of Natera shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 5.1% of Natera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ascendis Pharma A/S currently has a consensus target price of $310.05, suggesting a potential upside of 19.14%. Natera has a consensus target price of $319.38, suggesting a potential downside of 0.43%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Natera has higher revenue and earnings than Ascendis Pharma A/S. Natera is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.93	-$258M	$12.89	20.19
Natera	$2.31B	20.05	-$208.16M	-$1.36	N/A

Ascendis Pharma A/S has a net margin of 70.99% compared to Natera's net margin of -7.11%. Ascendis Pharma A/S's return on equity of 32.54% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Natera	-7.11%	-11.38%	-7.87%

Summary

Ascendis Pharma A/S beats Natera on 9 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Revolution Medicines presently has a consensus price target of $200.74, suggesting a potential downside of 4.35%. Ascendis Pharma A/S has a consensus price target of $310.05, suggesting a potential upside of 19.14%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05

Ascendis Pharma A/S has a net margin of 70.99% compared to Revolution Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, Revolution Medicines had 36 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 70 mentions for Revolution Medicines and 34 mentions for Ascendis Pharma A/S. Revolution Medicines' average media sentiment score of 0.84 beat Ascendis Pharma A/S's score of 0.49 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	33 Very Positive mention(s)	10 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	5 Very Negative mention(s)	Positive
Ascendis Pharma A/S	5 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ascendis Pharma A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,884.59	-$1.13B	-$8.82	N/A
Ascendis Pharma A/S	$814.57M	19.93	-$258M	$12.89	20.19

Summary

Ascendis Pharma A/S beats Revolution Medicines on 10 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Biogen?

Ascendis Pharma A/S (NASDAQ:ASND) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Ascendis Pharma A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.93	-$258M	$12.89	20.19
Biogen	$9.89B	3.23	$1.29B	$5.65	38.24

87.9% of Biogen shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 70.99% compared to Biogen's net margin of 8.32%. Ascendis Pharma A/S's return on equity of 32.54% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Biogen	8.32%	11.18%	6.88%

In the previous week, Biogen had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 36 mentions for Biogen and 34 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 1.30 beat Ascendis Pharma A/S's score of 0.49 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	29 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S presently has a consensus target price of $310.05, suggesting a potential upside of 19.14%. Biogen has a consensus target price of $227.79, suggesting a potential upside of 5.44%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Ascendis Pharma A/S beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Ascendis Pharma A/S (NASDAQ:ASND) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Alnylam Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.93	-$258M	$12.89	20.19
Alnylam Pharmaceuticals	$3.71B	8.87	$313.75M	$5.38	45.75

Ascendis Pharma A/S presently has a consensus target price of $310.05, indicating a potential upside of 19.14%. Alnylam Pharmaceuticals has a consensus target price of $386.14, indicating a potential upside of 56.90%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

Ascendis Pharma A/S has a net margin of 70.99% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 34 mentions for Ascendis Pharma A/S and 28 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.05 beat Ascendis Pharma A/S's score of 0.49 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	5 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	20 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Ascendis Pharma A/S on 9 of the 16 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASND vs. The Competition

Export

Metric	Ascendis Pharma A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.41B	$3.93B	$7.15B	$12.83B
Dividend Yield	N/A	3.61%	2.53%	11.78%
P/E Ratio	20.19	11.87	271.62	24.97
Price / Sales	19.93	1,328.30	613.31	86.39
Price / Cash	N/A	106.63	77.20	52.85
Price / Book	9.72	16.59	12.92	6.03
Net Income	-$258M	-$22.72M	$3.47B	$348.89M
7 Day Performance	4.00%	-2.26%	-0.99%	-2.29%
1 Month Performance	6.70%	11.57%	7.14%	2.94%
1 Year Performance	30.67%	52.33%	23.90%	14.08%

Ascendis Pharma A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASND Ascendis Pharma A/S	4.4944 of 5 stars	$260.25 -1.1%	$310.05 +19.1%	+34.0%	$16.41B	$814.57M	20.19	1,189	Trending News Analyst Forecast Analyst Revision
MRNA Moderna	1.5254 of 5 stars	$138.89 -4.3%	$74.31 -46.5%	+540.4%	$57.94B	$1.94B	N/A	4,700	Trending News Options Volume Analyst Revision
NTRA Natera	2.4649 of 5 stars	$327.72 -1.3%	$319.38 -2.5%	+90.6%	$47.86B	$2.71B	N/A	6,140	Positive News
RVMD Revolution Medicines	2.4797 of 5 stars	$211.58 +1.0%	$167.89 -20.6%	+452.7%	$44.89B	$11.58M	N/A	250	Analyst Forecast Analyst Revision
BIIB Biogen	3.6418 of 5 stars	$218.12 +0.6%	$227.07 +4.1%	+63.4%	$32.03B	$9.89B	38.61	7,500	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASND) was last updated on 9/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Competitors

ASND vs. MRNA, NTRA, RVMD, BIIB, and ALNY

How does Ascendis Pharma A/S compare to Moderna?

Summary

How does Ascendis Pharma A/S compare to Natera?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Competitors

ASND vs. MRNA, NTRA, RVMD, BIIB, and ALNY

How does Ascendis Pharma A/S compare to Moderna?

Which has higher valuation & earnings, ASND or MRNA?

Which has more risk and volatility, ASND or MRNA?

Is ASND or MRNA more profitable?

Do analysts prefer ASND or MRNA?

Does the media prefer ASND or MRNA?

Do institutionals & insiders have more ownership in ASND or MRNA?

Summary

How does Ascendis Pharma A/S compare to Natera?

Which has more risk & volatility, ASND or NTRA?

Does the media prefer ASND or NTRA?

Do institutionals and insiders believe in ASND or NTRA?

Do analysts rate ASND or NTRA?

Which has stronger valuation & earnings, ASND or NTRA?

Is ASND or NTRA more profitable?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Do analysts recommend RVMD or ASND?

Is RVMD or ASND more profitable?

Which has more risk & volatility, RVMD or ASND?

Does the media favor RVMD or ASND?

Do institutionals & insiders hold more shares of RVMD or ASND?

Which has preferable valuation and earnings, RVMD or ASND?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Which has more risk and volatility, ASND or BIIB?

Which has preferable valuation & earnings, ASND or BIIB?

Do insiders & institutionals hold more shares of ASND or BIIB?

Is ASND or BIIB more profitable?

Does the media refer more to ASND or BIIB?

Do analysts rate ASND or BIIB?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Which has higher earnings & valuation, ASND or ALNY?

Do analysts prefer ASND or ALNY?

Is ASND or ALNY more profitable?

Does the media refer more to ASND or ALNY?

Do institutionals and insiders believe in ASND or ALNY?

Which has more volatility & risk, ASND or ALNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools